Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9RJH7)

• Drug Name: Zaltoprofen Drug Info
• Synonyms: Zaltoprofen (unspecified); Zaltoprofene; Zaltoprofeno; Zaltoprofenum; CN 100; CN-100; Soleton; zaltoprofen; (+-)-2-(10,11-Dihydro-10-oxodibenzo(b,f)thiepin-2-yl)propionic acid; 10,11-Dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid; 2-(10,11-Dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic Acid; 2-(10-oxo-10,11-dihydrodibenzo[b,f]thiepin-2-yl)propanoic acid; 2-(6-oxo-5H-benzo[b][1]benzothiepin-3-yl)propanoic acid; 74711-43-6; 89482-00-8; AK-77321; C17H14O3S; EINECS 277-973-5; NCGC00183878-01; Peon
• Cross-matching ID:
  PubChem CID: 5720
  ChEBI ID: CHEBI:32306
  CAS Number: CAS 74711-43-6
  TTD Drug ID: DM9RJH7
  INTEDE Drug ID: DR1726

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[2]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[3]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[5]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[5]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[7]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[8]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[9]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[10]

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B7 (UGT2B7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[11]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[12]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[1]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[13]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[14]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[1]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[15]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[16]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[17]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[18]

Drug(s) Metabolized By Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[1]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[1]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[1]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[1]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[1]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[1]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[1]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[1]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[1]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[1]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[1]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[1]

References

• [1] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [2] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [3] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [4] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [5] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [6] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [7] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [8] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [9] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [10] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [11] Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
• [12] Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
• [13] Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
• [14] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [15] Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
• [16] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [17] Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
• [18] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [19] Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.